Patent Grant
8075879
The Sequence Listing filed herewith is incorporated by reference.
The field of this invention is microbial genetics, especially as related to immunogenic compositions comprising attenuated bacterial pathogens or components thereof.
The Brucella species are important zoonotic pathogens affecting a wide variety of mammals. In agriculturally important domestic animals, these bacteria cause abortion and infertility, and they are of serious economic concern worldwide (5). In humans, Brucella species constitute potential bio-warfare agents. Brucella species that infect humans cause in undulating fever, which if untreated, can manifest as orchitis, osteoarthritis, spondylitis, endocarditis, and neurological disorders (11, 46). Currently there is no vaccine to protect against human brucellosis, especially that caused by B. melitensis. Treatment of brucellosis requires a prolonged combination of antibiotic therapy and is still problematic because of the potential for relapse.
Identifying Brucella virulence factors has been of great interest in understanding Brucella pathogenesis and immune evasion. After entry into macrophages virulent Brucella cells reside in an acidified vacuole, the Brucella containing vacuole (BCV). The BCV transiently interacts with early endosomes, followed by VirB-dependent sustained interaction with the endoplasmic reticulum (7). Thus, the BCV matures into a replicative niche in a VirB-dependent manner (7, 8). VirB proteins forming the type IV secretion system (T4SS) constitute important factors for Brucella virulence and intracellular replication (9, 14, 34). Lipopolysaccharide (LPS) is also an important virulence factor (27). Brucella LPS has minimal endotoxic effect, blocks complement activation, and protects against bactericidal cationic peptides (28). The O-chain is also important for the conventional entry of Brucella into macrophages through lipid rafts, a route which avoids fusion of the BCV with lysosomes (33, 37). Cyclic β-1, 2 glucan has been shown as an important virulence factor required for intracellular survival of Brucella (3). Although T4SS, cyclic β-1, 2 glucan, and LPS are clearly virulence factors of Brucella, the attenuated mutants lacking these virulence factors are either considered not safe or insufficient information is available to use them as vaccines for humans. This has necessitated identification of additional vaccine targets.
Several genetic loci that are required for Brucella replication in vitro have been identified (14, 24). In vitro conditions may not adequately reflect in vivo infection, and therefore, findings may have little or no in vivo relevance (45). In vivo screening methods have been used to identify Brucella genes required for survival and persistence (18, 26), however, these previous studies have relied on the conventional approach of determining tissue-specific cell counts (CFU) from multiple animals at different times, a process that is labor intensive and requires large numbers of animals. Because infection is a dynamic process and varies within individual mice, monitoring disease progression temporally within the same mouse provides a more comprehensive picture of pathogenic events. Further, such real-time analysis may reveal virulence determinants responsible for tissue specific replication of bacteria that would not be revealed using conventional CFU enumeration from liver and spleen.
Bioluminescent imaging of mice allows direct visualization of the infection process and is highly useful for bacterial pathogenesis studies (10), because the intensity of bioluminescence strongly correlates with the number of bacteria in the infected organs (16, 40). Bioluminescent imaging is useful in analyzing sub-acute and chronic infections that are often difficult to assess using conventional approaches because of uncertain bacterial locations (16, 40).
There is a long felt need in the art for safe and effective vaccines that protect humans and animals from infection by the pathogenic Brucella species, especially B. melitensis.
The present invention provides attenuated mutants of Brucella, including Brucella abortus and Brucella melitensis, which are useful in generating protective immunity to infection by virulent Brucella, including Brucella melitensis and Brucella abortus. In particular, mutants in which the galE gene (ORF BMEI0921 or the corresponding gene in other species of Brucella) is inactivated are useful in live vaccine formulations and mutants in which one or more peptidoglycan biosynthetic genes are functionally inactivated, i.e., the genes encoding the lytic murein transglycosylase and/or β-hexosaminidaseare inactivated, for example polar mutations in the operon in which these genes are expressed, with the disruption eliminating all, four or three genes within the relevant operon (ORFs BMEI1087-1090 in B. melitensis or corresponding genes/operon in other species of Brucella) are not functionally expressed. See Tables 5 and 6 and SEQ ID NOs:26 and 27. The mutations resulting in the attenuated phenotype due to inactivation of galE can be insertion, substitution or deletion mutations. With respect to the peptidoglycan related genes, it is not entirely sufficient to eliminate functional expression of only the dGTP phosphohydrolase gene to produce a mutant which is attenuated enough to be a desirable vaccine strain. Where the galE-like mutant of B. melitensis is used, it is recommended that the genetic background into which the mutation is introduced is a 16M genetic background.
Also within the scope of the present invention, are attenuated mutants of other species of Brucella, including Brucella abortus, B. suis, B. ovis, etc, where the functionality of the corresponding gene(s) as described above are destroyed. The coding sequence identified by ORFs BMEI1087-1090 are presented in Tables 5 and 6; see also the corresponding regions of SEQ ID NO:26-27. In strains and species other than B. melitensis 16M, from which the sequence information of Tables 5 and 6 is derived, the corresponding genes will have at least 85% or higher nucleotide sequence identity, thus enabling the generation of equivalent mutants in these coding sequences. Such mutants, when administered as live vaccines, provide an immune response to the cognate species of Brucella.
Within the present invention, there is at least one attenuated strain of Brucella in which there is a mutation which functionally inactivates or prevents expression of at least one of the galE and having at least 85% nucleotide sequence identity to SEQ ID NO:28, the gene encoding lytic murein transglycosylase and having at least 85% nucleotide sequence identity to nucleotides 7908-10817 of SEQ ID NO:26, β-hexosaminidase and having at least 85% nucleotide sequence identity with nucleotides 6688-7740 of SEQ ID NO:26, or a gene encoding deoxyguanosinetriphosphate triphosphohydrolase and having at least 85% nucleotide sequence identity with nucleotides 2138-3346 of SEQ ID NO:27. Also encompassed are immunogenic compositions for administration to a human or animal comprising an attenuated strain of the present invention. The bacterial cells in the composition can be killed or live, advantageously alive.
Further embodied within the present invention are immunogenic compositions comprising live cells of attenuated Brucella cells, and a pharmaceutically acceptable carrier. These attenuated Brucella cells can be deficient in the functional expression of at least one gene selected from the group consisting of galE, lytic murein transglycosylase and β-hexosaminidase. Such compositions include vaccine compositions for use in humans, sheep, goats, cattle, bison and other susceptible animals. It is understood that the immunization with one particular species of Brucella results an immune response primarily to same species as administered. Thus, for protection against B. melitensis, it is desired to administer an immunogenic composition comprising at least one live attenuated B. melitensis mutant, as set forth herein. These compositions can further comprise an agent which stimulates the immune response, for example, an interleukin such as interleukin 12.
The present invention further provides methods for generating an immune response, especially a protective immune response in humans, sheep, goats, and other animals. Desirably, the immune response generated is a T cell response. A single injection with live cells of least one attenuated Brucella mutant strain (desirably from 103 to 108 viable cells of each strain) as set forth above can trigger a protective immune response in the human or animal to which it has been administered, due to the persistence of the bacterial within the body of that animal. The immunogenic composition can be administered by any route of administration, such as subcutaneous, intramuscular, intraperitoneal, intravenous, mucosal, intradermal and so on. Because of the ability of the attenuated mutants of the present invention to persist in the body, it is not necessary for there to be repeated administrations of the immunogenic composition, although booster immunizations may be given.
Also within the scope of the present invention are attenuated mutants of Brucella strains having the same or equivalent defects to those of GR024 and GR026, as described herein, in which the hly gene (listeriolysin O) of Listeria monocytogenes is expressed. This results in brucella-infected cells which are “leaky”, thus resulting in a more effective immune response.
The present invention further provides methods for identifying B. melitensis peptides that correspond to MHC class I-restricted T cell epitopes, especially those associated with MHC class I (H-2 Kd).
Applicants have deposited samples of Brucella melitensis strains GR026 and Brucella melitensis strain GR01090Δ with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2700 on May 3, 2011, in accordance with the provisions of the Budapest Treaty, and these strains have been assigned the following identification numbers: PTA-11877, and PTA-11878, respectively. Each of these strain deposits will be maintained without restriction in the ATCC depository for a period of 30 years, or 5 years after the last request, or for the effective life of the patent, whichever is longer, and will be replaced if the deposit becomes non-viable during that period. Upon grant of a patent, all restrictions imposed by the depositor on the availability to the public of the deposited biological material will be irrevocably removed.
Additionally, the present invention provides a number of peptides that are associated with intracellular survival strategies of Brucella. These include several derived from an extracellular serine protease (BMEEII0148), characterized by a carboxy terminal region (amino acids 2349-2554) with high sequence homology to the β-domains of autotransporters of the Type V Secretory Systems of bacterial pathogens.
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
Spleens were scored on loss of white and red pulp architecture at 4× magnification; (−) normal spleen or no noticeable changes, (+) enlarged follicles, increased cellularity, and white pulp, (++) hyperplasia, with a significant increase in follicle size, and white pulp. (+++); increased red pulp and loss of white pulp architecture.
Certain bioluminescent mutants of B. melitensis are avirulent in IRF-1−/− mice. IRF-1−/− mice are highly susceptible and succumb to virulent Brucella infection; however, their response varies with the virulence of the Brucella strains (21, 22). Therefore, attenuated strains can be readily identified using these mice. We tested the three EZ::TN/lux bioluminescent mutants, GR019, GR024 and GR026 in IRF-1−/− mice to determine the virulence and pathology associated with these strains. In addition, we also tested two other B. melitensis mutants, BM710, a rough strain and Rev-1, a vaccine strain, so that the bioluminescent mutants could be evaluated for their ability to confer protection against challenge with virulent B. melitensis. IRF-1−/− mice (n=4) infected with bioluminescent strains were monitored for bacterial dissemination and persistence. Bioluminescence spread systemically in GR019 infected mice by day 1 post infection (PI), however, in the GR024 or GR026 infected mice bioluminescence localized primarily at the injection site (
GR019, but not GR024 or GR026, is attenuated in RAW macrophages. We examined the growth of bioluminescent mutants in RAW macrophage-like cells. All three insertion mutant strains exhibited growth rates similar to that of the virulent parent strain 16M with a duplication time of 2 hr in brucella broth suggesting no general growth defects in GRO19, GRO24 and GRO26 (
To determine the EZ::TN/lux insertion site in GR019, GR024, GR026, we performed ‘rescue cloning’ of the R6KΔori present in EZ::TN transposon from genomic DNA of each strain. Nucleotide sequencing of the rescued R6K plasmid clones in both orientations identified the transposon insertion in VirB4 (BMEII0028) for GR019, GalE homolog (BMEI0921, SEQ ID NO:28) for GR024, and in the intergenic region of BMEI1090-1091 (nucleotides 2138-3839 of SEQ ID NO:27) for GR026 (
To determine the gene(s) likely responsible for the observed phenotype of GR026, we created non-polar mutations in BMEI1090 (complement of nucleotides 2138-3346 of SEQ ID NO:27) and 1091 (nucleotides 3513-3839 of SEQ ID NO:27) by allelic replacement. The respective ORFs were replaced with a kanr marker by homologous recombination and resulting strains, GR-1090Δ and GR-1091Δ, were tested for virulence in IRF-1−/− mice. IRF-1−/− mice infected with GR-1091Δ died within 10 days similar to virulent 16M; however, only two mice infected with GR-1090Δ died and the remaining mice survived for at least 21 days (Table 2). The livers and spleens from the surviving mice had an average CFU of 6.65E+04 and 1.14E+06, respectively. Therefore inactivation of 1090 resulted in partial attenuation suggesting the phenotype associated with GR026 is likely due to altered expression of I1090 (complement of nucleotides 238-3346) and its downstream genes.
To confirm that the attenuation of bioluminescent mutants is due to disruption of transposon insertion targets and not due to secondary mutations, we complemented GR019, GR024 and GR026 with the corresponding ORFs. Because GR019 has a growth defect in RAW macrophages, the GR019 containing either pBBVirB4 or pBBVirB were tested for growth in these macrophages. Introduction of pBBVirB4 into GR019 resulted in partial restoration of the ability to grow in macrophages, as reflected by increase in intracellular bacteria at 24 hr PI (
Because both GR024 and GR026 agglutinated in the presence of acriflavin, we tested the GR024 and GR026 complemented strains for agglutination. GR024 complemented with pBBGalE resulted in no agglutination in the presence of acriflavin. Our earlier results suggested that the observed phenotype for GR026 is due to the altered expression of 11090 and its downstream genes, so we complemented GR026 with a plasmid containing 4 ORFs likely to form an operon (12). Surprisingly, addition of pBB1087-90 to GR026 resulted in much more pronounced agglutination, as seen with rough strains of Brucella. The functions encoded by BMEY1087-1090 are β-hexosaminidase, soluble lytic murein transglycosylase, arginyl tRNA synthetase and deoxyguanosinetriphosphate triphosphohydrolase (See Tables 5-6 and SEQ ID NOs:26-27). Consistent with the acriflavin agglutination results, both GR024 and GR026 were partially resistant to smooth-type specific Tbilisi (Tb) phage, and the addition of pBBGalE restored the susceptibility of GR024 to Tb phage. However, GR026 complemented with pBBI1087-90 was completely resistant to Tb phage suggesting a rough phenotype of the complemented strain.
GR024 and GR026 protect IRF-1−/− mice from virulent challenge. IRF-1−/− mice, though immuno-compromised, have been shown to generate a protective immune response following vaccination with attenuated strains (22). Therefore, we tested the abilities of the attenuated bioluminescent mutants to protect IRF-1−/− mice from virulent challenge. IRF-1−/− mice (n=9) were vaccinated by intraperitoneal injection with 1×107 CFU of each Brucella strain, and 60 days after vaccination, the mice were challenged with 1×106 CFU of virulent bioluminescent B. melitensis strain GR023 (40). IRF-1−/− mice vaccinated with attenuated bioluminescent mutants were challenged by intraperitoneal injection when no bioluminescent bacteria were detectable. The GR023 strain of B. melitensis was used for challenge studies to evaluate vaccine candidates for the ability to alter the dissemination and localization of virulent Brucella to different tissues as visualized temporally in individual mice by imaging. All mice vaccinated with either GR024 or GR026 survived for at least 44 days, where as only 2 mice vaccinated with GR019 and 3 mice vaccinated with BM710 survived for 44 days following challenge (
The livers and spleens from surviving mice vaccinated with different strains had very similar CFUs (CFU ranges; liver: 2.2E+02-1.2E+03, spleen: 1.5E+04 to 3.4E+04). Bacteria recovered from livers and spleens of mice vaccinated with bioluminescent strains were confirmed as the GR023 challenge strain by verifying the insertion site of EZ::TN<lux> using PCR. Bioluminescent imaging of vaccinated mice following i.p. challenge revealed strikingly different dynamics of persistence and spread of virulent bacteria. Unlike the unvaccinated mice, in all vaccinated groups, bacterial spread was less extensive (See
IRF-1−/− mice are defective in multiple aspects of the immune system (44). Therefore, to better correlate the immune protection provided by the different attenuated strains, we tested these bacterial strains in wild type C57BL/6 mice, the parental strain of IRF-1−/− mice. C57BL/6 mice are susceptible to virulent Brucella infection naturally and serve as a relevant model in which to study Brucella pathogenesis and immune protection. To assess the protection by different attenuated strains, we monitored bacterial clearance and histological changes in livers and spleens. In addition, the dynamics of infection by attenuated bioluminescent strains and their effects on virulent challenge were monitored by imaging. Similar to IRF-1−/− mice, GR019 vaccinated C57BL/6 mice had bioluminescence in systemic organs by day 1 PI; however, in GR024 or GR026 vaccinated mice bioluminescence was detected primarily at the injection site (
Mice are used extensively to study Brucella pathogenesis; however, the interpretation of data is often limited to CFU or histological changes observed in specific tissues. These approaches have limited our understanding of the dynamics of Brucella dissemination and localization into tissues beyond those organs that are conventionally used for evaluation. In this report, we describe the infection dynamics of three attenuated bioluminescent mutants in mice by visualizing how infection disseminates, bacterial preference to organs, contribution of certain Brucella genes to pathogenesis, and effect of vaccination on the dynamics of virulent bacterial infection. GR019, GR024, GR026, and BM710 were all attenuated in IRF-1−/− mice; however, Rev-1 remained virulent in these mice. Imaging of mice infected with bioluminescent strains revealed striking differences in bacterial dissemination and persistence. GR019 (VirB4), unlike GR024 or GR026, spread systemically and bioluminescence was observed in liver, spleen, testes, submandibular region and extremities early in infection, suggesting that the VirB system is not important for establishing early infection. However, the VirB system is required for Brucella persistence because C57BL/6 mice cleared GR019 infection faster than virulent Brucella. GR024 (GalE) and GR026 (90-91IR), on the other hand, failed to disseminate systemically (
Both GR024 and GR026 exhibited growth patterns in macrophages intermediate between those of smooth and rough strains of Brucella (41), and both strains produced very fine agglutination particles in the presence of acriflavin and were partially resistant to smooth-type specific Tb phage, suggesting that they have an altered surface structure (30). In GR024, the transposon insertion is in ORF BMEI0921 (SEQ ID NO:28), a NAD dependent epimerase/dehydratase family member that is closely related to enterobacterial galE. The galE gene is an important virulence factor in many Gram negative bacteria and is involved several cellular processes including cell membrane biogenesis (15, 17, 29, 32, 39, 42). The galE mutants in other bacteria possess defective LPS, reflecting a contribution of galE to LPS biogenesis. Likewise, acriflavin agglutination and phage susceptibility tests suggest a defect in the GR024LPS; however, GR024 was not sensitive to galactose. The galE mutants of other bacteria display a variable response to galactose, with some being sensitive while others are not sensitive to galactose (15, 19, 39). The B. melitensis genome contains another member of the NAD dependent epimerase/dehydratase family, BMEII0730. BMEII0730 is more closely related to UDP-glucose 4-epimerases from members of the α-proteobacteria and shares no homology with BMEI0921 (SEQ ID NO:28). A few bacterial species have two functional galE genes. In Yersinia enterocolitica one galE gene is linked to galactose utilization genes and the other linked to the LPS synthesis genes (39). However, neither of the Brucella galE genes is linked to galactose metabolic genes or to LPS biosynthetic genes. Although our results indicate that BMEI0921 plays a role in cell membrane biogenesis, whether it is involved in galactose utilization is not clear because the growth of GR024 was not inhibited in galactose-containing medium. Brucella genome annotation suggest that Brucella BMEII0730 is linked to sugar metabolism genes and may be involved in galactose utilization.
GR026 has an insertion in the intergenic region between BMEI1090 (complement of nucleotides 2138-3346 of SEQ ID NO:27) and 1091 (nucleotides 3513-3839 of SEQ ID NO:27). Further, selective allelic replacement of BMEI1090 or BMEI10191 supported the conclusion that loss of function of BMEI1090 and its downstream genes is responsible for the attenuation of GR026 (Table 1). BMEI1090 (complement of nucleotides 2138-3346 of SEQ ID NO:27) or BMEI10191 (nucleotides 3513-3839 of SEQ ID NO:27) encode HesB protein and a theoretical protein, respectively. Without wishing to be bound by any particular theory, we have concluded that 1090 and its downstream genes (1087-1090; Tables 5-6, SEQ ID NOs:26-27) form an operon. BMEI1087 (complement of nucleotides 159-1916 of SEQ ID NO:26) encodes α-hexosaminidase A, while BMEI1088 (complement of nucleotides 7908-10819 of SEQ ID NO:26) encodes soluble lytic murein transglycosylase, and these are involved in amino sugar metabolism and N-glycan biosynthesis (kegg database). Therefore, this operon may contribute to cell membrane and/or wall biogenesis. Consistent with this observation the acriflavin agglutination and Tb phage susceptibility tests suggested that GR026 has a surface structure defect. Complementation of GR026 with a plasmid containing BMEI1087-1090 ORFs resulted in more pronounced agglutination and complete resistance to Tb phage suggesting that the expression of these genes are under strict regulation.
Both GR024 and GR026 protected IRF-1−/− mice from virulent B. melitensis challenge, whereas highly attenuated GR019 and BM710 failed to protect these mice. In addition, GR024 and GR026 vaccinated mice displayed minimal changes in livers and spleens and no bioluminescence was observed at 44 days post-challenge. IRF-1−/− mice are defective in multiple immune components with reduced numbers of CD8+T cells, functionally impaired natural killer cells, and dis-regulation of IL-12 p40 and inducible nitric oxide synthase (44). Though these mice are severely immuno-compromised, they mount an adaptive immune response sufficient to protect against virulent challenge and protection is vaccine strain dependent. Unlike, GR019, both GR024 and GR026 produced a localized but persistent infection in these mice (
While the immunization strategy has been described using particular mutants of B. melitensis it is understood that corresponding mutants can be made in other species of Brucella, for use in immunogenic compositions and vaccination strategies for protection of the cognate species of Brucella. It is understood that there may be some immunological cross reactivity between species of Brucella, the most effective protection is afforded by immunization with an attenuated mutant of the same species as that for which protection is sought.
Further to the particular insertion and deletion mutants or those having equivalent loss of function as GRO24 and GRO26 described herein, immunogenic compositions and vaccines can be prepared using such mutants in which the listeriolysin (hly) derived from Listeria monocytogenes is expressed. Expression of this protein results in phagosomes which are “leaky”. The intracellular bacteria from the phagosomes are released into the cytoplasm of the cells in which they are reproducing, and there is a better immune response triggered. See, for example, Grode et al. (2005) J. Clin. Invest. 115: 2472-2479. For further discussions of listeriolysin, see also Giammerini et al. 2003. Protein Expr. Purif. 28:78-85; Dancz et al. 2002. J. Bacteriol. 184:5935-5945, Mengaud et al. 1988. Infect. Immun. 56:766-772 among others.
We have identified and analyzed B. melitensis-specific MHC class I-restricted T cell epitopes. There is additional data of MALDI-TOF Mass spectral analysis of such peptides naturally processed and associated with MHC class I molecules from macrophages infected with Brucella for 24 hrs. We have identified over 2500 peptides identified as Brucella associated with MHC class I (2Kd). These include peptides derived from the ORFs, as identified in Table 4.
Analysis of the peptides associated with MHC class I (2Kd) has revealed that a number of the peptides are likely associated with proteins previously unknown to be a part of Brucella's intracellular survival strategies. For example, one of the identified peptides is from an extracellular serine protease (BMEII0148). This protein has a conserved β-domain at the carboxy-terminal region that has high sequence homology to the β-domains of autotransporters of the Type V secretory system of bacterial pathogens (see
As used herein, attenuated means that a bacterial strain is reduced in virulence as compared to a “wild-type” clinical strain that causes disease in a human or particular animal; the attenuated strain does not cause disease in the human or particular animal.
With reference to a mutation, functional inactivation of a gene means that there is little or no activity of the gene product. For example, where the gene encodes an enzyme, the encoded product has less than 10%, desirably less than 5% or less than 1% of the enzymatic activity of the product from the wild type gene or there is less than 10%, less than 5% or less than 1% of the expression product. That is to say that the coding sequence can be interrupted with an inserted nucleotide or sequence, partly or wholly deleted or there can be a substitution mutation that changes the amino acid sequence of the encoded protein such that activity is significantly reduced. Alternatively, there can be an insertion, deletion or change in transcription and/or translation regulatory sequences such that expression is reduced or prevented at the level of gene transcription and/or translation of mRNA.
When a compound is claimed, it should be understood that compounds known in the art including the compounds disclosed in the references disclosed herein are not intended to be included. When a Markush group or other grouping is used herein, all individual members of the group and all combinations and subcombinations possible of the group are intended to be individually included in the disclosure.
Every formulation or combination of components described or exemplified can be used to practice the invention, unless otherwise stated. Specific names of compounds and/or genes or mutants are intended to be exemplary, as it is known that one of ordinary skill in the art can name the same compounds differently. One of ordinary skill in the art will appreciate that methods, starting materials, mutagenic methods, compositions, vaccine regiments and immunogenic composition ingredients other than those specifically exemplified can be employed in the practice of the invention without resort to undue experimentation. All art-known functional equivalents, of any such methods, starting materials, genetic methods, and formulations and vaccination regiments are intended to be included in this invention. Whenever a range is given in the specification, for example, a temperature range, a time range, or a composition range, all intermediate ranges and subranges, as well as all individual values included in the ranges given are intended to be included in the disclosure.
As used herein, “comprising” is synonymous with “including,” “containing,” or “characterized by,” and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. As used herein, “consisting of” excludes any element, step, or ingredient not specified in the claim element. As used herein, “consisting essentially of” does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim. Any recitation herein of the term “comprising”, particularly in a description of components of a composition or in a description of elements of a device, is understood to encompass those compositions and methods consisting essentially of and consisting of the recited components or elements. The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations not specifically disclosed herein.
An immunogenic composition is one which triggers either a humoral immune response or a cellular (T cell) response, or both, in a human or animal to which the compositions has been administered. A vaccine (or vaccine composition) is an immunogenic composition, which after administered to a human or animal, which results in either no infection or infection without less severe or no symptoms upon challenge with a virulent strain of the same microorganism as the vaccine composition contained. In the context of the present invention, cellular immune responses are especially important in protecting a human or animal against infection by virulent B. melitensis.
The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.
In general the terms and phrases used herein have their art-recognized meaning, which can be found by reference to standard texts, journal references and contexts known to those skilled in the art, unless otherwise defined herein.
In the present context, functionally inactivated means that a gene does not produce a biologically active gene product (there is less than 10% of the normal enzymatic activity or ligand binding activity). In the present context biological activity does not encompass triggering an immune response in a mammalian host in which the functionally inactivated gene product is expressed. However, it is intended that functionally inactivated includes those cases in which the gene is not expressed, for example, due to a large (or polar) insertion in a promoter region or other untranslated sequence.
The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition (see e.g. Fingl et. al., in The Pharmacological Basis of Therapeutics, 1975, Ch. 1 p. 1). It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity, or to organ dysfunctions, or to other negative effects. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an administered dose in the management of the disorder of interest will vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and dose frequency, also varies according to the age, body weight, and response of the individual patient or animal. A program comparable to that discussed above also may be used in veterinary medicine.
Use of pharmaceutically acceptable carriers to formulate the immunogenic compositions herein disclosed for the practice of the invention into dosages suitable for administration is within the scope of the invention. With proper choice of carrier and suitable manufacturing practice, the compositions of the present invention, in particular those formulated as solutions, may be administered parenterally, such as by intravenous injection. Appropriate compounds can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration.
Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. The preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions, including those formulated for delayed release or only to be released when the pharmaceutical reaches the small or large intestine.
The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levitating, emulsifying, encapsulating, entrapping or lyophilizing processes.
Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
Pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The compositions and methods and accessory methods described herein are representative of preferred embodiments and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims.
Monoclonal or polyclonal antibodies, preferably monoclonal, specifically reacting with a protein or other cellular component of interest may be made by methods known in the art. See, e.g., Harlow and Lane (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratories; Goding (1986 and subsequent editions) Monoclonal Antibodies: Principles and Practice, 2d ed., Academic Press, New York.
Standard techniques for cloning, DNA isolation, amplification and purification, for enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like, and various separation techniques are those known and commonly employed by those skilled in the art. A number of standard techniques are described in Sambrook et al. (1989) Molecular Cloning, Second Edition, Cold Spring Harbor Laboratory, Plainview, N.Y.; Maniatis et al. (1982) Molecular Cloning, Cold Spring Harbor Laboratory, Plainview, N.Y.; Wu (ed.) (1993) Meth. Enzymol. 218, Part I; Wu (ed.) (1979) Meth Enzymol. 68; Wu et al. (eds.) (1983) Meth. Enzymol. 100 and 101; Grossman and Moldave (eds.) Meth. Enzymol. 65; Miller (ed.) (1972) Experiments in Molecular Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.; Old and Primrose (1981) Principles of Gene Manipulation, University of California Press, Berkeley; Schleif and Wensink (1982) Practical Methods in Molecular Biology; Glover (ed.) (1985) DNA Cloning Vol. I and II, IRL Press, Oxford, UK; Hames and Higgins (eds.) (1985) Nucleic Acid Hybridization, IRL Press, Oxford, UK; and Setlow and Hollaender (1979) Genetic Engineering: Principles and Methods, Vols. 1-4, Plenum Press, New York. Abbreviations and nomenclature, where employed, are deemed standard in the field and commonly used in professional journals such as those cited herein.
All references cited herein are hereby incorporated by reference to the extent there is no inconsistency with the present disclosure. These references indicate the level of skill in the relevant arts.
The following examples are provided for illustrative purposes, and are not intended to limit the scope of the invention as claimed herein. Any variations in the exemplified articles which occur to the skilled artisan are intended to fall within the scope of the present invention.
Bacterial strains and plasmids used in this study are listed in Table 1. Strains GR019, GR024, and GR026 are the EZ::TN-lux transposon insertional mutants of B. melitensis 16M containing the promotorless lux operon. A schematic illustration of the bioluminescence transposon and the mutagenesis and analysis strategy is shown in
Suicide vectors pGR026-90K and pGR026-91K for generating deletions in BMEI1090 (complement of nucleotides 2138-3346 of SEQ ID NO:27) and BMEI1091 (nucleotides 3513-3839 of SEQ ID NO:27), respectively, were created using pZErO-1. To construct pGR026-90K, approximately 1 kb DNA sequences upstream and downstream of the deletion target was amplified by PCR (upstream: forward 5′atcaacggtaccCGTTCAGCGCGTCGAGATCG (SEQ ID NO:1) and reverse 5′gctctaggatccGACTGATAATTATGCCGTGCG (SEQ ID NO:2), downstream: forward 5′acagtcgga tccATAACCGAAGCCTATTCCTTC (SEQ ID No;3) and reverse 5′ggtaacctgcagCGAACGTGCCCGCAT CAT (SEQ ID NO:4)) and cloned into pZErO-1 to generate plasmid pGR026-90. Appropriate restriction sites were included in the PCR primers to facilitate the insertion of the kanamycin resistance (kanr) gene from pUC4K between the 2 fragments to generate pGR026-90K. Bases added to the 5′ end of each primer to provide restriction sites are underlined. To construct pGR026-91 K, the desired deletion target was amplified with approximately 1 kb upstream and downstream sequences using specific primers (forward 5′agatacggtaccTCTTCCATCGTTCCGGGCCT (SEQ ID NO:5) and reverse 5′catgcatctagaGACGCCGTTGATGTTCCATGTA (SEQ ID NO:6)) and cloned into pZErO-1 to generate pGR026-91. Then, inverse PCR was performed on pGR026-91 using primers (5′tcttgagaattcCCCAATGCGACCGCTT (SEQ ID NO:7) and 5′gattcagaattcTTTGGCGATCCGCCTGGCA (SEQ ID NO:8)) designed to amplify all but the deletion target. The inverse PCR product was digested with restriction enzyme and ligated to the kanr gene fragment to generate the final suicide vector pGR026-91 K.
To construct plasmids pBBVirB4, pBBGalE, and pBB11087-90, DNA sequences encoding the respective ORFs were amplified using primers (VirB4: forward-5′agagagGGTA CCCATGTTCATATTGCCGCTGATCG (SE1Q ID NO:9) and reverse-5′agagagGGATCCTGCTGGTTACA GTCAGGGCGAAT (SEQ ID NO:10); GalE: forward 5′agagagGGTACCAAAGCCCGGTAAAACGATTGATG (SEQ ID NO:11) and reverse 5′ agagagGGATCCGTTCCGGCATTTTCTGGCAAA (SEQ ID NO:12); 1087-90: forward-5′agagag ACTAGTTGTGCCGTCGTTTCCACCTG (SEQ ID NO:13) and reverse-5′ agagagCTCGAGAGGGACGGGGA TCGGGTTAT (SEQ ID NO:14). PCR products were digested with restriction enzymes and ligated to pBBR-MCS4 to generate the complementation plasmids.
The site of transposon insertion in GR019, GR024, and GR026 mutants was identified by rescue cloning. Two micrograms of genomic DNA from each strain was digested to completion with NcoI to generate a fragment with intact transposon and flanking sequences. Digested DNA was religated using a FastLink DNA ligation kit (Epicentre). Ligations were dialyzed and transformed into electrocompetent EC100 Dpir+ cells (Epicentre) and plated on LB agar containing kanamycin. Two independent kanr colonies were selected, the plasmid was extracted and the site of insertion was identified by sequencing the plasmid DNA bi-directionally using outward primers (40). Sequencing was performed using dye terminators at the DNA sequencing core facility, University of Wisconsin Biotechnology Center. Sequences were compared to the 16M genome sequence to determine the site of insertion.
For Southern hybridization, 10 μg of genomic DNA was digested with ClaI and separated in a 0.7% agarose gel by electrophoresis. The single copy insertion of the transposon at the expected location was detected using the kanr gene as a probe. A 700 bp internal fragment of the kanr gene was amplified from pUC4K using primers, KanF2; 5′GCTCGAGGCCGC GATTAAAT (SEQ ID NO:15) and KanR2; 5′TCACCGAGGCAGTTCCATAGGA (SEQ ID NO:16), labeled with North2South Direct HRP detection and labeling kit (Pierce) and used as a probe.
To generate specific deletions, suicide vectors pGR026-90K and pGR026-91K were electroporated into B. melitensis 16M. Cells were plated on brucella agar containing kanamycin. To select for double recombinants, the kanr colonies were checked for sensitivity to zeocin (zeos). The resulting kanr and zeos clones were streak purified, and one such purified clone was used for further study.
The macrophage-like RAW 264.7 cells were cultured in RPMI supplemented with 10% heat-inactivated fetal calf serum. For macrophage growth assays, 24-well microtiter plates were seeded with 5×105 macrophages/well and infected with different B. melitensis strains at 1:50 multiplicity of infection. Cells were incubated for 1 hr at 37° C. in 5% CO2, extracellular bacteria were removed with 3 washes of PBS followed by treatment with gentamicin 25 μg/ml for 30 min. Following gentamicin treatment, the cells were maintained with medium containing 5 μg of gentamicin/ml. At specified times, cells were washed with PBS three times, lysed with 0.1% Triton-X, and plated on brucella agar to determine intracellular bacterial counts. All experiments were performed in duplicate.
Groups of 6-9 week old IRF-1−/− (n=4) were infected intra-peritoneally (i.p.) with 1×107 CFU of GR019, GR024, GR026, Rev-1 and BM710 strains. Infected mice were housed in a biosafety level 3 facility and monitored for survival (virulent Brucella kills these mice within 14 days; 21). For imaging, mice were anesthetized with isoflurane, and bioluminescence was recorded after a 10 min exposure using a CCD camera (Xenogen, Alameda, Calif.). From the surviving mice, livers and spleens were collected aseptically, homogenized in PBS and plated on brucella agar. Plates were incubated at 37° C. for 4 days, and CFU were determined. For histology, a portion of livers and spleens were collected and fixed in 10% formalin, 5 μm sections were prepared, stained with hemotoxylin and eosin and microscopically examined.
IRF-1−/− mice 6-9 weeks old (n=9/group) were vaccinated with 1×107 CFU i.p. with B. melitensis strains GR019, GR024, GR026, or BM710 in 200 μl PBS. As a control, a group of 10 mice were injected with 200 μl PBS. Similarly, C57BL/6 mice (n=20/group) were vaccinated i.p. with 5×107 CFU with each of the above strains and the Rev-1. Mice were imaged daily using a CCD camera until challenge. After 60 days, both IRF-1−/− and C57BL/6 mice were challenged with 1×106 CFU of virulent bioluminescent B. melitensis GR023 i.p. Following challenge, mice were imaged with 10 min exposure using a CCD camera and dissemination of virulent bioluminescent GR023 in different groups was monitored.
For IRF-1−/− mice, the survival was recorded in different groups following virulent challenge. At 44 days post challenge, livers and spleens from surviving mice were processed for CFU enumeration. For C57BL/6 mice, to determine CFU in livers and spleens, 4 mice from each group were killed at weekly intervals. Portions of the livers and spleens were weighed and then homogenized in PBS. Homogenates were serially diluted, plated on brucella agar with or without antibiotic and colonies were counted after 72 hr of incubation at 37° C. To determine the histological changes at each time, a portion of livers and spleens were collected, fixed in 10% formalin, and 5 μm sections were prepared and stained with hematoxylin and eosin.
Raw264.7 mouse macrophage cells (haplotype H2d) are infected (MOI 1000) with B. melitensis cells for 48 hrs. Infected cells, along with uninfected control cells (2×109 each) are harvested by scraping, and membrane proteins are extracted using Mem-PER (Pierce Chemical Co., Rockford, Ill.). The extract is dialyzed overnight in 0/5% CHAPS buffer to prepare for immunoprecipitation. H2-Dd/peptide co-immunoprecipitation is performed using Seize Primary Immunoprecipitation Kit (Pierce) couple with anti-mouse H-2Dd monoclonal antibody that recognizes a conformationally sensitive epitope of H-2Dd (5589125, BD Biosciences Pharmingen, San Diego, Calif.). After elution of the MHC I/peptide complex in acidic conditions, the peptides are separated from MHC I components by passing through a 5 kDa MWCO filter (Millipore, Billerica, Mass.). Micro BCA protein assays are performed on the peptide mix, and the peptides are separated, sequenced and analyzed by liquid chromatograph/mass spectrometry.
Alternatively, the RAW264.7 mouse macrophage cells are infected with invasive E. coli expressing GFPuv for identification of infected cells (MOI 100 24 hr infection). The results demonstrated that MHC I and associated peptide can be identified, and the invasive E. coli vaccine vector can be used to deliver antigen to cells for processing and presentation by MHC class I. In this example, of eight H2-Dd nonamers from Infected Raw264.7 cells, one (NYNSHNVYI, SEQ ID NO:17) was specific to the GFPuv protein. Other sequenced peptides included HYLSTQSAL (SEQ ID NO:18), LFTGVVPIL (SEQ ID NO:19), KFICTTGKL (SEQ ID NO:20), DFKEDGNIL (SEQ ID NO:21), LPVPWPTLV (SEQ ID NO:22), EYNYNSHNV (SEQ ID NO:23) and TPIGDGPVL (SEQ ID NO:24).
E. coli strain used for cloning
E. coli strain used for rescue cloning
B. melitensis 16M vaccine strain
B. melitensis 16M with BMEI1090 replaced
B. melitensis 16M with BMEI1091 replaced
aCFU counts and tissue damage were assessed two weeks post infection except for the 16M and GR023 infected groups for which tissues were collected when mice were moribund.
bLiver damage was assessed based on the number of focal granulomas and spleen damage was assessed based on the loss of architecture of white and red pulp. Tissue sections were visualized at 4X magnification and damage was assessed by observing more than 5 fields of view.
cSurvived for at least 3 weeks.
dNot determined
Brucella strains following a virulent challenge.
aLivers were scored by the number of focal granulomas observed per field of view at 4X magnification. At each time, 8 fields were counted to determine the number of granulomas: (+) 1-8; (++) 9-16; (+++) 17-24; (++++) 25-32; (+++++) 33-40 granulomas.
bSpleens were scored on loss of white and red pulp architecture. At each time, 8 fields (4X) were scored using the following criteria: (−) normal spleen or no noticeable changes; (+) enlarged follicles, increased cellularity, and white pulp; (++) hyperplasia, with a significant increase in follicle size, and white pulp; (+++) increased red pulp, early loss of architecture, and the diminution of white pulp; (++++) severe loss of architecture, and a dramatic reduction in the number of follicles.
Brucella peptides identified from MHC I molecules*
Brucella melitensis 16M
B. melitensis 16M (SEQ ID NO: 28).
Although the description herein contains many specific examples and descriptions, these should not be construed as limiting the scope of the invention but as merely providing illustrations of some of the presently preferred embodiments of the invention. For example, thus the scope of the invention should be determined by the appended claims and their equivalents, rather than by the examples given.
This application is a Continuation of U.S. application Ser. No. 11/633,371, filed Dec. 1, 2006, which claims benefit of U.S. Provisional Application No. 60/741,282, filed Dec. 1, 2005; both applications are incorporated by reference herein to the extent there is no inconsistency with the present disclosure.
This invention was made with government support under Grant Nos. R01AI048490 and AI057153 awarded by the National Institutes of Health (NIH/NIAID. The government has certain rights in the invention.
| Number | Name | Date | Kind |
|---|---|---|---|
| 5830702 | Portnoy et al. | Nov 1998 | A |
| Number | Date | Country |
|---|---|---|
| WO 2005084706 | Sep 2005 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20100158954 A1 | Jun 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60741282 | Dec 2005 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11633371 | Dec 2006 | US |
| Child | 12580213 | US |
